-+undefined NaN%
-+undefined NaN%
-+undefined NaN%

BMO Capital Downgrades Fate Therapeutics to Market Perform From Outperform, Adjusts Price Target to $7 From $20

BMO Capital Downgrades Fate Therapeutics to Market Perform From Outperform, Adjusts Price Target to $7 From $20

MT Newswires · 01/06/2023 02:52